VRAX · Virax Biolabs Group Limited

Summary

Virax Biolabs Group Limited reported that all outstanding Pre-Funded Warrants to purchase 12,500,000 ordinary shares have been exercised as of April 10, 2026, resulting in a total of 19,923,432 ordinary shares outstanding.

Key takeaways

• All 12,500,000 Pre-Funded Warrants issued in the December 2025 private placement have been exercised.
• The exercise of warrants increases the total ordinary shares outstanding to 19,923,432.
• The warrants were originally issued as part of a $5,000,000 gross proceeds financing transaction.
• The Pre-Funded Warrants had a nominal exercise price of $0.0001 per share.
• The company had previously disclosed the warrant issuance in a Form 6-K filed on December 4, 2025.